Holen Sie sich die Stockscreener-App
567.90
0.65%
3.675
Handel nachbörslich:
567.90
Schlusskurs vom Vortag:
$564.23
Offen:
$563
24-Stunden-Volumen:
209.55K
Relative Volume:
0.87
Marktkapitalisierung:
$33.96B
Einnahmen:
$1.86B
Nettoeinkommen (Verlust:
$-40.29M
KGV:
-136.51
EPS:
-4.16
Netto-Cashflow:
$-1.28B
1W Leistung:
-3.57%
1M Leistung:
+0.51%
6M Leistung:
+55.24%
1J Leistung:
+15.95%
1-Tages-Spanne:
$561.00
$569.42
1-Wochen-Bereich:
$561.00
$603.23
52-Wochen-Spanne:
$327.73
$611.22
Argen X Se Adr Stock (ARGX) Company Profile
Vergleichen Sie ARGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Inkl
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com
argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India
William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India
Raymond James maintains outperform on argenx, cites strong sales - Investing.com India
argenx stock climbs as Truist highlights industry-leading I&I pipeline growth - Investing.com India
Stifel sees upside in argenx stock with robust pipeline and solid 3Q results - Investing.com
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP - Investing.com Nigeria
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $589.6 amid robust growth - Investing.com
argenx ADR earnings beat by $1.24, revenue topped estimates - Investing.com
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - The Bakersfield Californian
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - GlobeNewswire Inc.
argenx SE's SWOT analysis: biotech firm's stock poised for growth amid challenges - Investing.com
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $555.55 amid robust growth - Investing.com
Argenx stock soars to all-time high of $555.55 amid robust growth By Investing.com - Investing.com South Africa
Jefferies’ updated ‘Franchise picks’: CPAY, KVUE, SAIA, PFGC (S&P Complete Indices:SP500) - Seeking Alpha
argenx shares receive Strong Buy rating on CIDP approval - Investing.com India
Piper Sandler maintains Overweight rating on argenx shares - Investing.com
Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com India
Halozyme expands argenx collaboration with $30M deal - Investing.com
Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs - Investor's Business Daily
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):